Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2011 2
2012 1
2013 2
2014 3
2017 3
2018 6
2019 3
2020 7
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

26 results
Results by year
Filters applied: . Clear all
Page 1
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Salles G, Duell J, González Barca E, Tournilhac O, Jurczak W, Liberati AM, Nagy Z, Obr A, Gaidano G, André M, Kalakonda N, Dreyling M, Weirather J, Dirnberger-Hertweck M, Ambarkhane S, Fingerle-Rowson G, Maddocks K. Salles G, et al. Among authors: obr a. Lancet Oncol. 2020 Jul;21(7):978-988. doi: 10.1016/S1470-2045(20)30225-4. Epub 2020 Jun 5. Lancet Oncol. 2020. PMID: 32511983 Clinical Trial.
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.
Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, Blakkisrud J, Løndalen A, O'Rourke N, Beasley M, Jurczak W, Fagerli UM, Kaščák M, Bayne M, Obr A, Dahle J, Rojkjaer L, Pascal V, Holte H. Kolstad A, et al. Among authors: obr a. Blood Adv. 2020 Sep 8;4(17):4091-4101. doi: 10.1182/bloodadvances.2020002583. Blood Adv. 2020. PMID: 32877524 Free PMC article. Clinical Trial.
A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma.
Obr A, Klener P, Furst T, Kriegova E, Zemanova Z, Urbankova H, Jirkuvova A, Petrackova A, Malarikova D, Forsterova K, Cudova B, Sedlarikova L, Berkova A, Kasalova N, Papajik T, Trneny M. Obr A, et al. Br J Haematol. 2020 Dec;191(5):e103-e106. doi: 10.1111/bjh.17063. Epub 2020 Aug 30. Br J Haematol. 2020. PMID: 32862455 No abstract available.
Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy.
Malarikova D, Berkova A, Obr A, Blahovcova P, Svaton M, Forsterova K, Kriegova E, Prihodova E, Pavlistova L, Petrackova A, Zemanova Z, Trneny M, Klener P. Malarikova D, et al. Among authors: obr a. Cancers (Basel). 2020 Jul 31;12(8):2120. doi: 10.3390/cancers12082120. Cancers (Basel). 2020. PMID: 32751805 Free PMC article.
Group I p21-activated kinases in leukemia cell adhesion to fibronectin.
Kuželová K, Obr A, Röselová P, Grebeňová D, Otevřelová P, Brodská B, Holoubek A. Kuželová K, et al. Among authors: obr a. Cell Adh Migr. 2021 Dec;15(1):18-36. doi: 10.1080/19336918.2021.1872760. Cell Adh Migr. 2021. PMID: 33464167 Free PMC article.
26 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page